Epcoritamab (epcor) + chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) eligible for autologous stem cell transplant (ASCT): Pooled results from arms 4 and 10 of EPCORE NHL-2.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: U-M Rogel Cancer Center, Vall d'Hebron Hospital Universitari, University of California, San Francisco, The University of Western Australia, Sir Charles Gairdner Hospital, Cedars-Sinai Medical Center, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, Los Angeles Medical Center, Memorial Sloan Kettering Cancer Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Charles University, General University Hospital in Prague, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Universitat de Barcelona, AbbVie (United States), Genmab (United States), Genmab (Denmark), Hospital Universitario Fundación Jiménez Díaz
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162540222